Efficacy and Safety of Venetoclax-Based Induction Therapy in Acute Myeloid Leukemia

AbstractObjective: To investigate the efficacy and safety of venetoclax-based induction chemotherapy in newly diagnosed (ND) patients ineligible for intensive therapy and patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). The clinical data of 51 newly diagnosed patients ineligible...

Full description

Saved in:
Bibliographic Details
Published inZhongguo shi yan xue ye xue za zhi Vol. 31; no. 4; p. 960
Main Authors Feng, Juan, Yuan, Rui-Feng, Tang, Hai-Long, Bai, Qing-Xian, Yang, Lan, Dong, Hong-Juan, Liang, Rong, Zhang, Tao, Gu, Hong-Tao, Gao, Guang-Xun
Format Journal Article
LanguageChinese
Published China 01.08.2023
Subjects
newly diagnosed
acute myeloid leukemia
hypomethylating agent
venetoclax
relapsed/ refractory
Online AccessGet more information

Cover

More Information
Summary:AbstractObjective: To investigate the efficacy and safety of venetoclax-based induction chemotherapy in newly diagnosed (ND) patients ineligible for intensive therapy and patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). The clinical data of 51 newly diagnosed patients ineligible for intensive therapy and patients with R/R AML treated in the Department of Hematology of Xijing Hospital from February 1, 2021 to April 30, 2022 were retrospectively analyzed. The incidence of complete remission (CR)/CR with incomplete hematological recovery (CRi), objective remission rate (ORR), minimal residual disease (MRD) status, advense events (AE), overall survival (OS) and progression-free survival (PFS) were analyzed. Among 51 patients, 32 patients were newly diagnosed patients unfit for intensive therapy, with a median age of 60 (29-88) years, and 19 patients were R/R patients, with a median age of 49 (22-92) years. The median cycles of VEN-based treatment in the two groups were both 2. The CR/CRi rate
ISSN:1009-2137
DOI:10.19746/j.cnki.issn.1009-2137.2023.04.005